The Global Hereditary
Angioedema Market, by Drug Class (C1 Esterase Inhibitor, Kallikrein
Inhibitor, Bradykinin Receptor, Attenuated Androgens, and Others), By Route of
Administration (Subcutaneous, Intravenous, and Oral), by Distribution Channel
(Hospital Pharmacies, Retail Pharmacies, and e-Commerce) and by Region (North
America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was
valued at US$ 1,563.7 million in 2016 and is projected to exhibit a CAGR of 9.1%
over the forecast period (2017 – 2025).
The hereditary angioedema market
is expected to gain significant traction with the rising innovations for the
development of novel drugs by the manufacturers and increasing R&D
initiatives undertaken by research foundations.
Novel delivery platforms adopted
by manufacturers to drive the global market growth
Positive clinical trial results
integrated with assured safety profiles to cater the unmet need of the disease
are the major factors to augment the global hereditary angioedema market in the
foreseeable period. For instance, in 2016, RNAi-based candidate ARC-F12 by
Arrowhead Pharmaceuticals is currently in preclinical development and is a
potential treatment for factor XII (F12) mediated diseases. The RNAi based
candidate is expected to present opportunities in the treatment of hereditary
angioedema, thus the Arrowhead is currently conducting studies to advance the
candidate into the clinical trials. Furthermore, the novel gene therapy product
candidate by Adverum Biotechnologies named AADVM-053 is presently in the
preclinical trials for the treatment of patients HAE.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1292
ADVM-053 is an Adeno Associated
Virus (AAV) based gene transfer vector that aims to provide persistent levels
of human C1-esterase inhibitor (C1-INH) to potentially correct the deficiency
state that can lead to life-threatening attacks.
Browse 58 Market Data Tables and
32 Figures spread through 175 Pages and in-depth TOC on “Hereditary Angioedema
Market”- Global Forecast to 2025.
The key players are adopting
strategic collaborations and acquisitions for the development and expansion of
the HAE portfolio and to accelerate respective pipelines for faster delivery of
the products. For instance, In January 2018, BioCryst Pharmaceuticals and Idera
Pharmaceuticals merged to create a new rare-disease company. The companies
currently have two phase 3 clinical compounds, including BioCryst’s BCX7353 and
Idera’s IMO-8400. In 2017, Diplomat Pharmacy, Inc. acquired Focus Rx Pharmacy
Services Inc., to offer extensive solutions to meet the growing demand for
infusion therapies for individuals living with chronic conditions including
hereditary angioedema and other disorders. In 2015, Shire Plc acquired Dyax
Corp. with a strategy to get access and achieve worldwide sales of lead
pipeline product DX-2930, Phase 3-ready, fully-humanized monoclonal antibody.
The FDA granted DX-2930 fast track, breakthrough therapy, and orphan drug
designation in the EU.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/hereditary-angioedema-market-1292
Key Takeaways of the Hereditary
Angioedema Market:
The global hereditary angioedema
market is expected to exhibit a CAGR of 9.1% over the forecast period, owing to
the presence of high potential market and raising awareness of the condition in
Europe, Asia Pacific, and Latin America
Among drug class, C1 esterase
inhibitor segment holds a dominant position in the hereditary angioedema
market, owing to the robust number of drugs approved by the regulatory agencies
Some of the major players
operating in the global hereditary angioedema market include CSL Behring, Shire
Plc., Pharming Healthcare, Inc., BioCryst Pharmaceuticals, Inc., Ionis
Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Adverum Biotechnologies and
Attune Pharmaceuticals, Inc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1292
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment